- Avalon GloboCare (AVCO -6.4%) completes Phase I first-in-human clinical study of its lead Chimeric Antigen Receptor (CAR) T-cell therapy candidate, AVA-001.
- Nine out of ten patients with relapsed/refractory B-cell acute lymphoblastic leukemia achieved complete remission (CR rate of 90%) within one month after the initiation of AVA-001 therapy.
- AVA-001 was generally well tolerated with minimal toxicities and adverse side effects; no neurotoxicity was observed.
- All patients who achieved CR successfully proceeded to allogeneic bone marrow transplant with curative intent.